{
    "url_original": "https://www.wsj.com/articles/purdue-pharma-authorized-to-appeal-judges-rejection-of-sackler-settlement-plan-11641589371?mod=business_lead_pos13",
    "url": "purdue-pharma-authorized-to-appeal-judges-rejection-of-sackler-settlement-plan-11641589371",
    "title": "Purdue Pharma Authorized to Appeal Judge’s Rejection of Sackler Settlement Plan",
    "sub_head": "The OxyContin maker is looking to revive its chapter 11 plan to resolve an onslaught of opioid lawsuits",
    "category_1": "Pro Bankruptcy",
    "image_1_url": "https://images.wsj.net/im-464151?width=860&height=573",
    "image_1": "im-464151.jpg",
    "time": "2022-01-07 16:02:00",
    "body": "A federal judge authorized Purdue Pharma LP and its Sackler family owners to appeal a ruling that threw out their $4.5 billion settlement of thousands of lawsuits linked to the bankrupt company’s OxyContin painkiller and its role in the opioid crisis.<br />Purdue has until Jan. 17 to apply to the Second U.S. Circuit Court of Appeals for an expedited appeal, U.S. District Judge Colleen McMahon of the Southern District of New York ruled."
}